Stock ULTI ULTIMOVACS ASA
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ultimovacs ASA

Equities

ULTI

NO0010851603

Biotechnology & Medical Research

Market Closed - Oslo Bors
Other stock markets
 10:45:00 2024-04-26 am EDT 		5-day change 1st Jan Change
7.1 NOK +2.45% Intraday chart for Ultimovacs ASA -14.56% -94.22%
Apr. 17 Ultimovacs to Reduce 40% of Workforce Amid Operational Adjustments MT
Apr. 17 Transcript : Ultimovacs ASA - Special Call

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,092 2,558 3,860 3,784 4,225 244.3 - -
Enterprise Value (EV) 1 692.5 2,117 3,288 3,364 4,225 -933.2 -805.2 -1,884
P/E ratio -17.9 x -21.2 x -22.1 x -22.4 x -22.3 x 0.43 x -1.86 x 1.15 x
Yield - - - - - - - -
Capitalization / Revenue - - - - - 0.26 x - 0.73 x
EV / Revenue - - - - - -0.98 x - -5.62 x
EV / EBITDA -10.8 x -17.4 x -20.4 x -18.6 x -19.8 x -1.25 x 5.79 x -6.95 x
EV / FCF -11 x -19.5 x -26.1 x -20 x - -1.49 x 5.61 x -7.78 x
FCF Yield -9.12% -5.13% -3.83% -4.99% - -67.1% 17.8% -12.8%
Price to Book 2.46 x 5.24 x 6.51 x 8.42 x - 0.67 x 1.09 x -
Nbr of stocks (in thousands) 27,860 31,974 34,222 34,396 34,406 34,406 - -
Reference price 2 39.20 80.00 112.8 110.0 122.8 7.100 7.100 7.100
Announcement Date 2/14/20 2/17/21 2/17/22 2/16/23 2/14/24 - - -
1NOK in Million2NOK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - 953.5 - 335
EBITDA 1 -64.15 -121.4 -161.1 -181 -213 748.5 -139 271
EBIT 1 -66.22 -124.1 -163.8 -183.6 -215.7 747 -140.5 271
Operating Margin - - - - - 78.34% - 80.9%
Earnings before Tax (EBT) 1 -61.17 -120.6 -164.7 -167.8 -189.2 747.3 -140.2 271
Net income 1 -61.17 -120.6 -164.7 -167.8 -189.2 654.3 -140.2 242
Net margin - - - - - 68.62% - 72.24%
EPS 2 -2.195 -3.770 -5.100 -4.900 -5.500 16.36 -3.820 6.200
Free Cash Flow 1 -63.16 -108.5 -125.9 -167.9 - 626.5 -143.5 242
FCF margin - - - - - 65.71% - 72.24%
FCF Conversion (EBITDA) - - - - - 83.7% - 89.3%
FCF Conversion (Net income) - - - - - 95.76% - 100%
Dividend per Share - - - - - - - -
Announcement Date 2/14/20 2/17/21 2/17/22 2/16/23 2/14/24 - - -
1NOK in Million2NOK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 400 441 572 420 - 1,178 1,050 2,128
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -63.2 -109 -126 -168 - 627 -144 242
ROE (net income / shareholders' equity) -20.2% -25.8% -30.5% -32.2% - 31.7% -27.6% 12%
ROA (Net income/ Total Assets) -18.3% -23.9% -27.6% - - -54% -38.7% -
Assets 1 334 503.9 596.3 - - -1,212 362.4 -
Book Value Per Share 2 16.00 15.30 17.30 13.10 - 10.70 6.520 -
Cash Flow per Share - - - - - - - -
Capex - - 0.09 0.2 - - - -
Capex / Sales - - - - - - - -
Announcement Date 2/14/20 2/17/21 2/17/22 2/16/23 2/14/24 - - -
1NOK in Million2NOK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
7.1 NOK
Average target price
6.5 NOK
Spread / Average Target
-8.45%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ULTIMOVACS ASA Stock Ultimovacs ASA
-94.22% 22.12M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ULTI Stock
  4. Financials Ultimovacs ASA